Fluticasone propionate is a synthetic glucocorticoid. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications. Fluticasone propionate was first approved in 1990.
Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxisas well as inflammatory and pruritic dermatoses. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis.
GSK Investigational Site, Hannover, Niedersachsen, Germany
Research Site, Milwaukee, Wisconsin, United States
GSK Investigational Site, Vienna, Austria
GSK Investigational Site, Wellington, New Zealand
Kaiser Permanente Medical Center, San Diego, California, United States
National Jewish Medical and Research Center, Denver, Colorado, United States
University of Wisconsin - Madison, Madison, Wisconsin, United States
GSK Investigational Site, Stockholm, Sweden
GSK Investigational Site, London, United Kingdom
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
National Jewish Medical and Research Center, Denver, Colorado, United States
University of California, San Francisco, San Francisco, California, United States
GSK Investigational Site, Hamburg, Germany
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.